X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

KURA

Closed

Kura Oncology Inc

5.6
-0.2 (-3.47%)
Last Update: 01 Jul 2025 23:04:00
Yesterday: 5.77
Day's Range: 5.575 - 5.88
Send
When Written:
 
12.39
Kura Oncology Inc is a clinical-stage biopharmaceutical company that focuses on the development of precision medicines for the treatment of cancer. The company's pipeline includes small molecule drug candidates that target specific oncogenic drivers and tumor suppressors. Kura Oncology's lead drug candidate, tipifarnib, is a selective inhibitor of farnesyl transferase that is being developed for the treatment of patients with solid tumors that harbor HRAS mutations. The company is also developing KO-947, a small molecule inhibitor of extracellular signal-regulated kinase (ERK), for the treatment of patients with tumors that have mutations in the MAPK pathway. Kura Oncology is headquartered in San Diego, California, and was founded in 2014.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.15
X